Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products ( i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recently, the eIF4A inhibitor eFT226 (zotatifin) has entered phase I/II clinical trials for estrogen receptor–positive metastatic breast cancer in combination with fulvestrant and abemaciclib (43, 44).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [43]
Citations
Cites
Fulmer, G. R., Miller, A. J. M., Sherden, N. H., Gottlieb, H. E., Nudelman, A., Stoltz, B. M., Bercaw, J. E., & Goldberg, K. I. (2010) · Organometallics · doi:10.1021/om100106e · Cited by 4,050
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer
Wolfe, A. L., Singh, K., Zhong, Y., Drewe, P., Rajasekhar, V. K., Sanghvi, V. R., Mavrakis, K. J., Jiang, M., Roderick, J. E., Van der Meulen, J., et al. (2014) · Nature · doi:10.1038/nature13485 · Cited by 635
Structure of the Exon Junction Core Complex with a Trapped DEAD-Box ATPase Bound to RNA
Andersen, C. B. F., Ballut, L., Johansen, J. S., Chamieh, H., Nielsen, K. H., Oliveira, C. L. P., Pedersen, J. S., Séraphin, B., Hir, H. L., & Andersen, G. R. (2006) · Science · doi:10.1126/science.1131981 · Cited by 438
New frontiers in translational control of the cancer genome
Truitt, M. L., & Ruggero, D. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.27 · Cited by 378
Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development
Pelletier, J., Graff, J., Ruggero, D., & Sonenberg, N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2789 · Cited by 367
Translation from unconventional 5′ start sites drives tumour initiation
Sendoel, A., Dunn, J. G., Rodriguez, E. H., Naik, S., Gomez, N. C., Hurwitz, B., Levorse, J., Dill, B. D., Schramek, D., Molina, H., et al. (2017) · Nature · doi:10.1038/nature21036 · Cited by 331
mRNA helicases: the tacticians of translational control
Parsyan, A., Svitkin, Y., Shahbazian, D., Gkogkas, C., Lasko, P., Merrick, W. C., & Sonenberg, N. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3083 · Cited by 323
Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor
Iwasaki, S., Floor, S. N., & Ingolia, N. T. (2016) · Nature · doi:10.1038/nature17978 · Cited by 313
Chen, X., Kopecky, D. J., Mihalic, J., Jeffries, S., Min, X., Heath, J., Deignan, J., Lai, S., Fu, Z., Guimaraes, C., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300037x · Cited by 222
Research works printed but not linked: 1
- Algar J., 1934, Proc. R. Ir. Acad., Sect. B, 42, 1
Cited by
Targeting RNA structures with small molecules
Childs-Disney, J. L., Yang, X., Gibaut, Q. M. R., Tong, Y., Batey, R. T., & Disney, M. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00521-4 · Cited by 587
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
White, K. M., Rosales, R., Yildiz, S., Kehrer, T., Miorin, L., Moreno, E., Jangra, S., Uccellini, M. B., Rathnasinghe, R., Coughlan, L., et al. (2021) · Science · doi:10.1126/science.abf4058 · Cited by 343
Cellular functions of eukaryotic RNA helicases and their links to human diseases
Bohnsack, K. E., Yi, S., Venus, S., Jankowsky, E., & Bohnsack, M. T. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00628-5 · Cited by 143
“The rocaglate derivative eFT226 (zotatifin) is undergoing clinical trials (NCT04092673) 298,299 .”
BackgroundLi, Y., Wang, Z., Li, Y., Du, J., Gao, X., Li, Y., & Lai, L. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03725-y · Cited by 92
“Caco-2 cell permeability data for 6083 compounds were collected from public sources [9– 11].”
Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A
Chen, M., Asanuma, M., Takahashi, M., Shichino, Y., Mito, M., Fujiwara, K., Saito, H., Floor, S. N., Ingolia, N. T., Sodeoka, M., et al. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.11.008 · Cited by 82
“, 2019), and a derivative (zotatifin or eFT226) (Ernst et al., 2020) is currently under clinical trial.”
Background
Metadata
- Authors
- Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., Eam, B., Young, N. P., Fish, S., Chen, J., Howard, H., Staunton, J., Molter, J., Clarine, J., Nevarez, A., Chiang, G. G., Appleman, J. R., Webster, K. R., & Reich, S. H.
- Affiliations
- Inception Therapeutics, 6175 Nancy Ridge Drive, San Diego, California 92121, United States
- eFFECTOR Therapeutics (United States) (US)
- Genentech (US)
- Gossamer Bio (United States) (US)
- WuXi AppTec (United States) (US)
- Calporta Therapeutics, 11099 North Torrey Poines Rd., La Jolla, California 92037, United States
- Casma Therapeutics (United States) (US)
- Plexium, Inc., 11585 Sorrento Valley Rd., San Diego, California 92121, United States
- Providence Portland Medical Center (US)
- Escient Pharmaceuticals, 10578 Science Center Dr., San Diego, California 92121, United States
- Primmune Therapeutics, 3210 Merryfield Row, San Diego, California 92121, United States
- Frontier Medicines (United States) (US)
- Corresponding author
- Ernst, Justin T.
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-05-29
- Volume
- 63
- Issue
- 11
- Pages
- 5879-5955
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3031081298
- Cited by
- 150
- References
- 41
- Citations by year
- 2026: 20 · 2025: 26 · 2024: 29 · 2023: 24 · 2022: 17 · 2021: 26 · 2020: 8
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- eIF4A, DEAD-box RNA helicase, eIF4F, cap-dependent translation, anticancer agents, ligand-based drug design, anticancer activity
- MeSH terms
- Animals, Benzofurans, Binding Sites, Breast Neoplasms, Female, Half-Life, Humans, Ligands, Mice, Nude, RNA, Messenger, Structure-Activity Relationship, Drug Design, Mutagenesis, Site-Directed, Protein Structure, Tertiary, Crystallography, X-Ray, Eukaryotic Initiation Factor-4A, Cell Line, Tumor, Mice, Rats, Molecular Dynamics Simulation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. https://app.cochat.ai/papers/10.1021/acs.jmedchem.0c00182
- The paper
- Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., Eam, B., Young, N. P., Fish, S., Chen, J., Howard, H., Staunton, J., Molter, J., Clarine, J., Nevarez, A., . . . Reich, S. H. (2020). Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.0c00182
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.